Greg Walden

Three lawmakers who will lead the U.S. House next year are among the biggest recipients of campaign contributions from the pharmaceutical industry.

The industry has given big bucks to U.S. Rep. Greg Walden, who chairs a powerful congressional committee, but has ignored Rep. Peter DeFazio, who is not on any committees that influence drug legislation.

Greg Walden, D-Ore., was one of two congressional lawmakers who has received more than $200,000 from pharmaceutical companies since January 2017.

Greg Walden, Oregon's only Republican in Congress, was one of two lawmakers who received more than $200,000 from pharmaceutical companies since January 2017.

December 19, 2012 -- U.S. Rep. Greg Walden (R-Ore.) today announced that he secured language requiring the Pentagon to detail and address upcoming changes to TRICARE Prime in this year’s defense authorization bill. The plan is based off legislation he, Rep. Suzanne Bonamici (D-Ore.), and Rep. Mark Amodei (R-Nev.) introduced earlier this month. It requires the Pentagon to assess the increased cost and overall impact that TRICARE changes will have on military retirees and their families, and, within 90 days, inform Congress of its plan to provide them with a smooth transition.

November 17, 2011 – Nine healthcare organizations – most of which advocate for people with chronic illnesses – are speaking up about proposed cuts to Medicare. A federal deficit “supercommittee” has one week left to cut $1.2 trillion within the next decade. While that committee may or may not meet its November 23 deadline, Medicare cuts are on the table.